The E75 Vaccine for Breast Cancer
Elizabeth Mittendorf, MD, PhD, from the University of Texas MD Anderson Cancer Center, gives an overview of how the E75 vaccine works in breast cancer.
Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, gives an overview of how the E75 vaccine works in breast cancer.
Patients with an excessive number of the HER2 protein or amplification of the gene will see benefit from treatment with trastuzumab, Mittendorf says.
Clinical Pearls
The E75 vaccine is a piece of the HER2 protein and is the best peptide with respect to presentation by antigen-presenting cells to be shown to T cells. E75 fits well into the HER2 story, Mittendorf says, as it is effective in patients with any degree of HER2 expression. For the vaccine to be effective, the immune system simply needs to recognize any amount of HER2.
- Patients with an excessive number of the HER2 protein or amplification of the gene will benefit from treatment with trastuzumab
- The E75 vaccine is a piece of the HER2 protein and has the appropriate sequence to be shown to immune cells
- E75 is effective in patients with any degree of HER2 expression
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
